Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 9Tumor-Agnostic 3Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × olaratumab × Tumor-Agnostic × Clear all
NCT02377752 2021-02-17

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
25 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT02677116 2020-05-20

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Eli Lilly and Company

Phase 1 Completed
68 enrolled 26 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01199822 2017-04-14

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Completed
16 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡